Catalog No.
PAD62601
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
Dupilumab
Tested applications
ELISA: 1:4000-1:8000
Target
Rabbit polyclonal to Dupixent.
Specificity
The product is specific for Dupilumab. This antibody serves as an excellent positive control for Dupilumab immunogenicity (ADA) assays.
Concentration
0.5 mg/ml
Purification
Purified by antigen affinity column.
Accession
CAS: 1190264-60-8
Applications
ELISA
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles.
Background
Dupilumab with trade name Dupixent, is an FDA-approved drug for the treatment of patients aged 6 years and older with moderate-to-severe atopic dermatitis. It is a human monoclonal antibody. Dupilumab binds to the interleukin-4 receptor alpha (IL-4Rα) subunit shared by the interleukin (IL)-4 and IL-13 receptor complexes, thereby inhibiting IL-4 and IL-13 signaling. Anti-Dupilumab Antibody, pAb, Rabbit is produced from sera of a rabbit immunized with Dupilumab.
Interleukin-4 and -13 Gene Expression Profiles in Immune-Related Bullous Pemphigoid Indicate Efficacy of IL-4/IL-13 Inhibitors., PMID:40507326
Dupilumab in an adolescent with eosinophilic esophagitis and eosinophilic duodenitis, a valuable treatment option., PMID:40504588
Dupilumab treatment has no effect on the nasal microbiome in patients with NSAID-exacerbated respiratory disease: a longitudinal pilot study., PMID:40503236
[Application and research progress of anti-IL-4α monoclonal antibody dupilumab in the treatment of type 2 asthma]., PMID:40491151
A nationwide experience of biological treatments in children with eosinophilic esophagitis., PMID:40483369
An unbiased tissue transcriptome analysis identifies potential markers for skin phenotypes and therapeutic responses in atopic dermatitis., PMID:40456762
Real-World Clinical Experience of Tralokinumab in a Tertiary Centre: An Alternative for Patients with Conjunctivitis on Dupilumab?, PMID:40442566
The interaction between the expression of CD23 molecule on B- lymphocytes and the level of specific IgE against molecular components of pollen in atopic dermatitis patients with and without dupilumab therapy., PMID:40432597
Long-Term Real-World Outcomes and Insights of Biologic Therapies in Chronic Rhinosinusitis with Nasal Polyps., PMID:40429838
Clinical Effectiveness, Clinical Stability, and Effects on Serum Galectin-7 Levels of Dupilumab and JAK Inhibitors in Moderate-to-Severe Atopic Dermatitis: A Real-World, Single-Center Analysis., PMID:40428884
Time to Disease Control with Dupilumab for Bullous Pemphigoid: A Systematic Review and Meta-analysis., PMID:40423583
Cutaneous T Cell Lymphoma Following Dupilumab Therapy in Patients with Atopic Dermatitis: Clinical Review and Recommendations., PMID:40418285
Effect of silicone oil on the structure, stability, and aggregation of a therapeutic antibody., PMID:40414350
Effects of Dupilumab in Children and Adolescents With Moderate-Severe Asthma: A Systematic Review of Clinical Trials., PMID:40396426
Chronic Obstructive Pulmonary Disease (COPD): Developments in Pharmacological Treatments., PMID:40392521
Expanding the potential of monoclonal antibodies against interleukin-4 and interleukin-13 in genodermatoses: A case series on the efficacy and safety of dupilumab in epidermolysis bullosa and ichthyosis., PMID:40386013
Expert Opinion on the Management, Challenges, and Knowledge Gaps Pertaining to Eosinophilic Esophagitis Among Adults in the Greater Gulf Region., PMID:40385617
Dupilumab for the Treatment of Cutaneous Immune-Related Adverse Events: A Systematic Review., PMID:40375468
Autoimmune bullous diseases: pathogenesis and clinical management., PMID:40372624
Mycosis fungoides and IL-4/13 inhibitors: what is known and unmet needs., PMID:40369852
Biologic Therapies for Severe Asthma: Current Insights and Future Directions., PMID:40364184
Long-Term Real-World Effectiveness of Dupilumab vs. Upadacitinib in Early Treatment Responders with Atopic Dermatitis: Results from Central European Health Fund Registry., PMID:40362473
A Sticky Situation: Case Series of Successful Treatment of Glue Ear With Dupilumab., PMID:40360240
Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse events., PMID:40355282
Dupilumab-associated lymphoproliferative disorders: a comprehensive review on clinicohistopathologic features and underlying mechanisms., PMID:40349527
Blocking of IL-4/IL-13 Signalling With Dupilumab Results in Restoration of Serum and Cutaneous Abnormalities in Netherton Syndrome., PMID:40344324
Switching to tezepelumab from other biologics in patients with severe asthma: a retrospective study., PMID:40339469
Ocular surface evaluation in atopic dermatitis patients on dupilumab: A prospective observational study., PMID:40339460
Editor's Highlights-June 2025., PMID:40322884
Dupilumab-Induced Psoriasis in a Patient With Prurigo Nodularis: A Case Report., PMID:40322378
Atopic dermatitis relapse after treatment discontinuation and predictive factors for relapse: JAK1 inhibitors versus dupilumab., PMID:40317605
Dupilumab in the Treatment of Pemphigoid Gestationis., PMID:40315477
Frequency and clinical features of disease flares in patients with atopic dermatitis treated with dupilumab., PMID:40298144
New and Emerging Biologics and Jak Inhibitors for the Treatment of Prurigo Nodularis: A Narrative Review., PMID:40282922
New Therapeutic Challenges in Pediatric Gastroenterology: A Narrative Review., PMID:40281872
Sustained Efficacy and Low Rate of Adverse Events of Dupilumab in Type-2 CRSwNP Over 48 Months., PMID:40265743
Sinonasal Intervention Reduces the Need for Pressure Equalization Tube Placement in Atopic Adults., PMID:40265713
Complete Resolution of Atypical Paraneoplastic Pemphigus Following Treatment With Dupilumab., PMID:40264631
Recalcitrant Nummular Eczema in Childhood Responsive to Dupilumab Treatment., PMID:40264610
Efficacy of Biologics in Reducing Exacerbations Requiring Hospitalization or an Emergency Department Visit in Patients with Moderate or Severe, Uncontrolled Asthma., PMID:40261563
Real-World pharmacovigilance analysis of drug-related conjunctivitis using the FDA adverse event reporting system database., PMID:40251175
Early Intervention with Mepolizumab, Corticosteroids, and Intravenous Immunoglobulin for Dupilumab-Triggered Eosinophilic Granulomatosis with Polyangiitis: A Case Report., PMID:40248105
Effectiveness of Dupilumab and Omalizumab in Bullous Pemphigoid: A Nationwide Retrospective Cohort Study., PMID:40237419
The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta-Analysis Study., PMID:40231941
Angiolymphoid hyperplasia with eosinophilia responded well to dupilumab in two cases., PMID:40229669
Treatment of allergic bronchopulmonary aspergillosis with biologics., PMID:40226607
Increased Incidence of COVID-19 Infection in Atopic Dermatitis Patients: A Real-World Cohort Study With Risk Factor Analysis., PMID:40219685
[Observation of the efficacy of dupilumab for treatment of atopic dermatitis in the elderly]., PMID:40219560
Ocular Side Effects of Dupilumab: A Comprehensive Overview of the Literature., PMID:40217936
[Chronic Pruritus: A Review of Its Pathophysiology and Current Treatments]., PMID:40214004
For research use only. Not for human or drug use.
